Internalization and presentation of myelin antigens by the brain endothelium guides antigen-specific T cell migration

  1. Melissa A Lopes Pinheiro
  2. Alwin Kamermans
  3. Juan J Garcia-Vallejo
  4. Bert van het Hof
  5. Laura Wierts
  6. Tom O'Toole
  7. Daniël Boeve
  8. Marleen Verstege
  9. Susanne MA van der Pol
  10. Yvette van Kooyk
  11. Helga E de Vries
  12. Wendy WJ Unger  Is a corresponding author
  1. VU university medical center, Netherlands
  2. VU University medical center, Netherlands
  3. VU University Medical Center, Netherlands
  4. ErasmusMC-Sophia Children's Hospital, Netherlands

Abstract

Trafficking of myelin-reactive CD4+ T-cells across the brain endothelium, an essential step in the pathogenesis of multiple sclerosis (MS), is suggested to be an antigen-specific process, yet which cells provide this signal is unknown. Here we provide direct evidence that under inflammatory conditions, brain endothelial cells (BECs) stimulate the migration of myelin-reactive CD4+ T-cells by acting as non-professional antigen presenting cells through the processing and presentation of myelin-derived antigens in MHC-II. Inflamed BECs internalized myelin, which was routed to endo-lysosomal compartment for processing in a time-dependent manner. Moreover, myelin/MHC-II complexes on inflamed BECs stimulated the trans-endothelial migration of myelin-reactive Th1 and Th17 2D2 cells, while control antigen loaded BECs did not stimulate T-cell migration. Furthermore, blocking the interaction between myelin/MHC-II complexes and myelin-reactive T-cells prevented T-cell transmigration. These results demonstrate that endothelial cells derived from the brain are capable of enhancing antigen-specific T cell recruitment.

Article and author information

Author details

  1. Melissa A Lopes Pinheiro

    Department of Molecular Cell Biology and Immunology, VU university medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  2. Alwin Kamermans

    Department of Molecular Cell Biology and Immunology, VU university medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  3. Juan J Garcia-Vallejo

    Department of Molecular Cell Biology and Immunology, VU university medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  4. Bert van het Hof

    Department of Molecular Cell Biology and Immunology, VU university medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  5. Laura Wierts

    Department of Molecular Cell Biology and Immunology, VU university medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Tom O'Toole

    Department of Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  7. Daniël Boeve

    Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  8. Marleen Verstege

    Department of Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  9. Susanne MA van der Pol

    Department of Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  10. Yvette van Kooyk

    Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  11. Helga E de Vries

    Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  12. Wendy WJ Unger

    Department of Pediatrics, ErasmusMC-Sophia Children's Hospital, Rotterdam, Netherlands
    For correspondence
    w.unger@erasmusmc.nl
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Gary L Westbrook, Vollum Institute, United States

Version history

  1. Received: November 19, 2015
  2. Accepted: June 22, 2016
  3. Accepted Manuscript published: June 23, 2016 (version 1)
  4. Version of Record published: July 25, 2016 (version 2)

Copyright

© 2016, Lopes Pinheiro et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,638
    views
  • 628
    downloads
  • 39
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Melissa A Lopes Pinheiro
  2. Alwin Kamermans
  3. Juan J Garcia-Vallejo
  4. Bert van het Hof
  5. Laura Wierts
  6. Tom O'Toole
  7. Daniël Boeve
  8. Marleen Verstege
  9. Susanne MA van der Pol
  10. Yvette van Kooyk
  11. Helga E de Vries
  12. Wendy WJ Unger
(2016)
Internalization and presentation of myelin antigens by the brain endothelium guides antigen-specific T cell migration
eLife 5:e13149.
https://doi.org/10.7554/eLife.13149

Share this article

https://doi.org/10.7554/eLife.13149

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Joanna C Porter, Jamie Inshaw ... Venizelos Papayannopoulos
    Research Article

    Background:

    Prinflammatory extracellular chromatin from neutrophil extracellular traps (NETs) and other cellular sources is found in COVID-19 patients and may promote pathology. We determined whether pulmonary administration of the endonuclease dornase alfa reduced systemic inflammation by clearing extracellular chromatin.

    Methods:

    Eligible patients were randomized (3:1) to the best available care including dexamethasone (R-BAC) or to BAC with twice-daily nebulized dornase alfa (R-BAC + DA) for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was the improvement in C-reactive protein (CRP) over time, analyzed using a repeated-measures mixed model, adjusted for baseline factors.

    Results:

    We recruited 39 evaluable participants: 30 randomized to dornase alfa (R-BAC +DA), 9 randomized to BAC (R-BAC), and included 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to the combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9 mg/L to 23.23 mg/L in R-BAC +DA participants versus a 99.5 mg/L to 34.82 mg/L reduction in the T-BAC group at 7 days; p=0.01. The anti-inflammatory effect of dornase alfa was further confirmed with subgroup and sensitivity analyses on randomised participants only, mitigating potential biases associated with the use of CC-BAC participants. Dornase alfa increased live discharge rates by 63% (HR 1.63, 95% CI 1.01–2.61, p=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, p=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, p=0.004).

    Conclusions:

    Dornase alfa reduces pathogenic inflammation in COVID-19 pneumonia, demonstrating the benefit of cost-effective therapies that target extracellular chromatin.

    Funding:

    LifeArc, Breathing Matters, The Francis Crick Institute (CRUK, Medical Research Council, Wellcome Trust).

    Clinical trial number:

    NCT04359654.

    1. Immunology and Inflammation
    Hee Young Kim, Yeon Jun Kang ... Won-Woo Lee
    Research Article

    Trained immunity is the long-term functional reprogramming of innate immune cells, which results in altered responses toward a secondary challenge. Despite indoxyl sulfate (IS) being a potent stimulus associated with chronic kidney disease (CKD)-related inflammation, its impact on trained immunity has not been explored. Here, we demonstrate that IS induces trained immunity in monocytes via epigenetic and metabolic reprogramming, resulting in augmented cytokine production. Mechanistically, the aryl hydrocarbon receptor (AhR) contributes to IS-trained immunity by enhancing the expression of arachidonic acid (AA) metabolism-related genes such as arachidonate 5-lipoxygenase (ALOX5) and ALOX5 activating protein (ALOX5AP). Inhibition of AhR during IS training suppresses the induction of IS-trained immunity. Monocytes from end-stage renal disease (ESRD) patients have increased ALOX5 expression and after 6 days training, they exhibit enhanced TNF-α and IL-6 production to lipopolysaccharide (LPS). Furthermore, healthy control-derived monocytes trained with uremic sera from ESRD patients exhibit increased production of TNF-α and IL-6. Consistently, IS-trained mice and their splenic myeloid cells had increased production of TNF-α after in vivo and ex vivo LPS stimulation compared to that of control mice. These results provide insight into the role of IS in the induction of trained immunity, which is critical during inflammatory immune responses in CKD patients.